SCHEMBL24791663

SCHEMBL24791663

NCc1ccc(-c2ccncn2)cc1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.51
LOXL2 Q9Y4K0 5/20 0.50
ADRB2 P07550 1/20 0.50
HRH3 Q9Y5N1 1/20 0.48
CYP2A6 P11509 1/20 0.46
TAAR1 Q96RJ0 1/20 0.42
ASIC3 Q9UHC3 1/20 0.41
HSP90AA1 P07900 1/20 0.39
MAPK10 P53779 2/20 0.39
MAPK14 Q16539 2/20 0.39
MAPK9 P45984 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPT P10636 1/20 0.38
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
GRM5 P41594 1/20 0.36
GSK3B P49841 1/20 0.36
ALOX5 P09917 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30872067 1.00 CYP2D6 (0.51) CYP2D6LOXL2ADRB2HRH3CYP2A6
SCHEMBL28848117 0.98 HRH3 (0.52) CYP2D6LOXL2ADRB2HRH3CYP2A6
SCHEMBL9903935 0.83 CYP2D6 (0.60) CYP2D6HSP90AA1MAPK10MAPK14MAPK9
SCHEMBL28135261 0.83 ADRB2 (0.46) CYP2D6LOXL2ADRB2HRH3CYP2A6
SCHEMBL2559714 0.81 CYP2D6 (0.51) CYP2D6HSP90AA1MAPK10MAPK14MAPK9
SCHEMBL6852363 0.81 CYP2D6 (0.51) CYP2D6HSP90AA1MAPK10MAPK14MAPK9
SCHEMBL13637172 0.81 CYP2D6 (0.60) CYP2D6MAPK9MAPTCYP11B1CYP11B2
SCHEMBL15651713 0.78 CYP2D6 (0.51) CYP2D6HSP90AA1MAPK10MAPK14MAPK9
SCHEMBL28103664 0.78 CA2 (0.46) CYP2D6MAPK14
SCHEMBL8499115 0.77 CYP2D6 (0.53) CYP2D6HSP90AA1MAPK10MAPK14MAPK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022263604-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIMIDINE-7-AMINE COMPOUNDS AS CDK INHIBITORS AND THEIR THERAPEUTIC USE Carrick Therapeutics Limited (IE) 2022-12-22 WO disclosed